Interventional, Open-label, Single-dose Trial Investigating the Absorption, Metabolism, and Excretion (AME) of Lu AF28996 Following a Single Oral Dosing of 14C-Lu AF28996 to Healthy Men
Latest Information Update: 09 Oct 2024
At a glance
- Drugs Lu AF28996 (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Lundbeck A/S
Most Recent Events
- 04 Oct 2024 Status changed from recruiting to completed.
- 07 May 2024 Status changed from not yet recruiting to recruiting.
- 01 Apr 2024 New trial record